Page 3 - Harbor Gate News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nascent Biotech Continues Anti-Dilution Campaign with Preemptive Settlement of Outstanding Convertible Note ACCESSWIRE 04 May 2021, 22:05 GMT+10 SAN DIEGO, CA / ACCESSWIRE / May 4, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ( Nascent Biotech , Nascent , or the Company ), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce further strides toward the elimination of toxic debt and dilution risk with the preemptive settlement of its outstanding convertible note liability (the Note ) held by Harbor Gate Capital LLC ( Harbor Gate ). Under the terms of the Note, Harbor Gate had the right to redeem the outstanding liability in the form of an equity conversion that presented dilution risk for Nascent shareholders. The Note s total value at the time of preemptive settlement was $115,000, which includes principal, accrued interest, and prepayment value.

Sean carrickExchange commissionHarbor gate capitalNascent biotech incSecurities exchangeNascent biotech inc formNascent biotechHarbor gateSecurities actSecurities exchange actPrivate litigation reform actசீன் கேரிக்பரிமாற்றம் தரகுபுதியது பயோடெக் இன்க்பத்திரங்கள் பரிமாற்றம்புதியது பயோடெக் இன்க் வடிவம்